This Pathology Lab Stock Rises 38% in 1 Year: Bonus Shares, a Debt-Free Parent and a Shrinking Promoter Stake

This pathology lab stock rose approximately 38% over the past year on a screen of NSE small-cap stocks ranked by 1-year return, dated 17 September 2026. The bonus-adjusted close was Rs 402.80 on 17 September 2025 against Rs 557.55 on 17 September 2026, up 2.99% on the day.

The company is Thyrocare Technologies Ltd (NSE: THYROCARE), a diagnostics business built on centralised testing and a large franchisee network. The Thyrocare share price story has two halves: an earnings recovery that lifted FY26 profit by roughly 79%, and parent API Holdings using this holding to repay its own borrowings, cutting promoter ownership from 71.06% to 51.02% in under a year.

Click Here – Get Free Investment Predictions

How Much Has This Pathology Lab Stock Returned in 1 Year?

The verified one-year price return is 38.42%, close to close, adjusted for the 2:1 bonus. Rs 1 lakh put into this pathology lab stock a year ago would be worth about Rs 1.38 lakh today, before the Rs 7 dividend.

Period	Reference close (Rs)	Price return
1 Month (17 Aug 2026)	618.60	-9.87%
6 Months (17 Mar 2026)	361.70	54.15%
1 Year (17 Sep 2025)	402.80	38.42%
3 Years (mid-Sep 2023)	189.83	193.71%
5 Years (mid-Sep 2021)	422.92	31.83%

The 3-year gain of roughly 194% shows how deep the 2023 slump was, when this pathology lab stock sat below Rs 190 after FY23 profit fell to Rs 64.36 crore. The 5-year figure of about 32% is weaker, because September 2021 was a peak.

The 1-month figure is negative. The Thyrocare share price hit a record Rs 662 on 12 August 2026 and has since slipped roughly 16%, for a reason covered below.

Why Did This Pathology Lab Stock Rise 38% in 1 Year?

Four dated events explain most of the move in this pathology lab stock: a bonus issue with a strong September 2025 quarter, a promoter block sale that brought domestic funds onto the register, the FY26 result on 7 May 2026, and the June 2026 quarter reported on 23 July 2026.

A First-Ever 2:1 Bonus Issue on 14 October 2025

The board approved its first bonus in 25 years on 14 October 2025, in a 2:1 ratio. The record date was 28 November 2025 and adjusted trading began on 2 December 2025. The same meeting reported an 82% jump in September quarter profit to Rs 47.81 crore on revenue of Rs 219.58 crore.

The bonus tripled the share count to about 15.4 crore, which is why reported earnings per share fell from Rs 17.08 in FY25 to Rs 10.24 in FY26 even as profit rose. Turnover in the pathology lab stock picked up afterwards.

The 24 October 2025 Promoter Block at Rs 1,252 a Share

Promoter entity Docon Technologies sold 53.33 lakh shares, about 10% of the company, at Rs 1,252 each on 24 October 2025 for roughly Rs 667.7 crore, a pre-bonus price worth about Rs 417 today. Domestic institutional holding in this pathology lab stock jumped from 13.47% to 20.51% by December 2025.

Block sales usually depress a share. This one did not, because the buyers were long-only funds, and that wider base helped the pathology lab stock find support near Rs 342.55 in March 2026.

FY26 Results on 7 May 2026: Profit Up About 79%

The full-year numbers were the turning point for this pathology lab stock. Consolidated revenue reached Rs 846.03 crore against Rs 702.18 crore, and net profit rose to Rs 162.85 crore from Rs 90.75 crore. The March 2026 quarter alone delivered Rs 48.70 crore, more than double the year-ago figure.

FY26 test volumes reached 209.6 million, roughly 23% higher. The board recommended a Rs 7 final dividend and appointed a new statutory auditor. From the March low the pathology lab stock ran almost uninterrupted into August.

Q1 FY27 on 23 July 2026: Volumes Up 28%

The June 2026 quarter confirmed the trend. Revenue was Rs 244.17 crore, up about 24% year on year, with net profit of Rs 51.33 crore, up roughly 34%. The EBITDA margin was near 32%, gross margins improved by more than 290 basis points on better supplier terms, and test volumes grew 28%.

Behind those numbers sit 11,700 franchisee locations and 44 laboratories, with about 1,700 net additions targeted in FY27. Management is divesting the imaging business and wants allergy and genomics testing at 15% to 20% of the portfolio within five years. A domestic brokerage raised its target on the pathology lab stock the next day.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Thyrocare Share Price and the Financials Behind It

Margins, not just volumes, drove the re-rating. The operating margin climbed from 25.97% in FY24 to 33.22% in FY26 and the net margin from 12.15% to 19.64%.

Quarter	Revenue (Rs Cr)	EBITDA (Rs Cr)	Net Profit (Rs Cr)	Operating Margin	Net Margin
Jun 2025	197.68	62.42	38.29	32.47%	20.17%
Sep 2025	219.58	74.40	47.81	34.49%	22.16%
Dec 2025	200.51	62.81	28.05	29.12%	17.10%
Mar 2026	228.26	79.40	48.70	35.71%	21.04%
Jun 2026	244.17	81.42	51.33	34.22%	21.74%

December 2025 is the weak quarter, with revenue at Rs 200.51 crore and profit at Rs 28.05 crore as margins fell to 29.12%. Holders of any pathology lab stock should expect that seasonality, since the December quarter carries fewer preventive check-ups and a softer infection season.

Annually, revenue moved from Rs 581.25 crore in FY24 to Rs 702.18 crore and then Rs 846.03 crore, while profit went from Rs 69.49 crore to Rs 90.75 crore and Rs 162.85 crore. FY26 operating cash flow was Rs 213.23 crore against capital spending of Rs 20.88 crore, so this is an asset light pathology lab stock, with debt to equity at 0.09.

Valuation is the counterweight. The pathology lab stock trades at a trailing PE of approximately 48.84 against an industry PE near 67, so it is priced below the sector, but a price to book of 16.75 is demanding. Market cap is around Rs 8,589 crore, return on equity approximately 27.85% and the dividend yield 2.59%.

Who Owns This Pathology Lab Stock Now?

Promoter holding has fallen from 71.06% in September 2025 to 51.02% after the August 2026 block, while domestic institutions moved from 13.47% to about 21%. That is the biggest structural change in this pathology lab stock.

Quarter	Promoters	FII	DII	Public
Jun 2025	71.06%	3.23%	14.54%	11.17%
Sep 2025	71.06%	4.85%	13.47%	10.63%
Dec 2025	60.93%	4.95%	20.51%	13.61%
Mar 2026	60.92%	5.37%	20.99%	12.71%
Jun 2026	60.92%	5.44%	20.92%	12.72%

The June 2026 register shows a small-cap fund at 5.99%, a healthcare fund at 5.57% and a midcap fund at 3.84%. Concentrated fund ownership supports a pathology lab stock on the way up and works against it if several funds trim together.

Why Does the PharmEasy Parentage Matter?

It matters because the controlling shareholder has been a forced seller of this pathology lab stock. Thyrocare has been controlled since 2021 by API Holdings, parent of the PharmEasy platform, through Docon Technologies, which bought roughly 66% for about Rs 4,546 crore in 2021.

API Holdings carried heavy debt from its own growth years and used this holding to service it. Docon sold a further 9.9%, or 1,57,69,696 shares, at Rs 624 to Rs 631.71 on 13 and 14 August 2026, raising about Rs 985.86 crore. Buyers included domestic funds, a life insurer and a sovereign wealth fund, and the pathology lab stock fell roughly 8%.

On 17 August 2026 the parent said it had repaid Rs 1,050 crore, turned debt-free, and released the entire pledge on Docon's remaining shares. The promoter block in this pathology lab stock is unencumbered for the first time since the takeover.

What a debt-free parent does next is the open question. Docon still holds 51.02%, a whisker above the majority line, so any further sale forces a decision about control, and that uncertainty sits on the pathology lab stock today.

What Are the Risks in This Pathology Lab Stock?

The biggest risk in this pathology lab stock is the promoter overhang, then valuation, competition and liquidity. None are theoretical for a company that has seen about 20% of its equity change hands in ten months.

Promoter Stake Overhang

Two large sales in under a year have taught the market to expect more. With Docon at 51.02% the buffer is thin, and for a pathology lab stock with concentrated ownership that is the risk most likely to cap the rating.

Valuation and Margin Sustainability

A price to book of 16.75 leaves no room for a bad year. Margin gains came partly from supplier terms and product mix, and both can reverse. One weak quarter, like December 2025, resets expectations for this pathology lab stock.

Competition and Pricing Pressure

Organised chains and online aggregators compete hard on price in preventive testing, and revenue per test in a franchisee network is lower than at a hospital-linked lab. Allergy testing, genomics and prenatal screening are the answer for this pathology lab stock, but adoption is unproven.

Liquidity, Volatility and Execution

Turnover is uneven: about 1.12 lakh shares by mid-session on 17 September 2026, against 6.6 lakh on 13 August 2026. A thin order book lets a small-cap pathology lab stock move several percent on modest flows, and this one has swung from Rs 342.55 to Rs 662 and back to Rs 557.55 inside twelve months. Add execution risk on the imaging divestment and the FY26 change of statutory auditor, routine in itself but worth tracking.

Download the Univest iOS App or Univest Android App to track the Thyrocare share price live

Thyrocare Share: Analyst View

Coverage of this pathology lab stock is thin, which is normal at this size. A domestic brokerage kept a buy rating on 24 July 2026 and raised its fair value from Rs 550 to Rs 650, roughly 17% above Rs 557.55.

Thyrocare Share Price Target

The only recent verified Thyrocare share price target is Rs 650, dated 24 July 2026. It sits below the 52-week high of Rs 662, so it is not an aggressive call, and any unverified target for this pathology lab stock should be ignored.

Working from levels instead, three references stand out: the Rs 342.55 low of March 2026, the Rs 624 floor of the August block where institutions bought size, and the Rs 662 record high. A sustained close above Rs 624 would suggest the block has been absorbed. The June quarter run rate annualises to close to Rs 205 crore of profit if margins hold, putting the pathology lab stock on a forward multiple in the low 40s.

Other Stocks to Track From the Same Return Screen

Beyond this pathology lab stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Schneider Electric Infrastructure with a 1-year return of 31.80%, Varroc at 31.78% and Balrampur Chini at 31.64%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this pathology lab stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

This pathology lab stock delivered a verified 38.42% return in the year to 17 September 2026, driven by FY26 profit of Rs 162.85 crore, a 2:1 bonus and a parent that cleared its debt. The business is performing, with 28% volume growth in the June quarter and margins above 32%.

The caution is that the Thyrocare share price is still 16% below its August peak, the promoter sits at 51.02%, and a price to book of 16.75 assumes current margins hold. Track the December quarter and any further promoter action, and speak to a SEBI-registered adviser before acting on this pathology lab stock.

Frequently Asked Questions

Which pathology lab stock rose 38% in 1 year?

Ans. Thyrocare Technologies (NSE: THYROCARE) is the pathology lab stock that gained 38.42% between 17 September 2025 and 17 September 2026, from a bonus-adjusted Rs 402.80 to Rs 557.55.

Why did the Thyrocare share price rise in the last year?

Ans. The rise came from an earnings recovery, with FY26 profit up about 79% to Rs 162.85 crore, plus a first-ever 2:1 bonus approved on 14 October 2025. The parent also turned debt-free in August 2026.

What were Thyrocare's Q1 FY27 results?

Ans. Thyrocare reported revenue of Rs 244.17 crore for the June 2026 quarter, up about 24%, with net profit of Rs 51.33 crore, up roughly 34%. Test volumes grew 28%.

Did the bonus issue inflate the one-year return?

Ans. No. The 2:1 bonus had a record date of 28 November 2025, and the 38.42% return quoted here is adjusted for it, so the gain in this pathology lab stock reflects real price appreciation rather than the change in share count.

How much of Thyrocare does PharmEasy's parent still own?

Ans. Docon Technologies, a subsidiary of API Holdings, held 51.02% after selling 9.9% in August 2026. Promoter holding is down from 71.06% in September 2025 through two block sales, and is now free of any pledge.

What is the 52-week high and low of the Thyrocare share price?

Ans. The 52-week high is Rs 662, reached on 12 August 2026, and the low is Rs 342.55 from 23 March 2026. The share traded at Rs 557.55 on 17 September 2026, about 16% below its peak.

Is there a verified analyst target for this pathology lab stock?

Ans. Yes, a domestic brokerage set a Thyrocare share price target of Rs 650 with a buy rating on 24 July 2026, raised from Rs 550 in May 2026. Coverage is limited, so this is not a consensus view.

Is this pathology lab stock a good buy after a 38% gain?

Ans. That depends on whether you accept a price to book of 16.75 and a promoter who has sold about 20% of the company in ten months. A pathology lab stock of this size is volatile and thinly traded, so a staggered approach and advice from a SEBI-registered adviser are sensible.